Filing Flows › Insight Molecular Diagnostics (IMDX) › Q4 2025
Insight Molecular Diagnostics (IMDX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 26, 2026
Insight Molecular Diagnostics (IMDX) reported revenue of $1.1M for the fourth quarter 2025 (Q4 2025), -23% from a year earlier and +338% from the quarter before.
Insight Molecular Diagnostics, Q4 2025: revenue $1.1M (-23% year over year), net loss $23.0M, operating cash flow −$5.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +338% | -23% |
| Operating profit | −$23.4M | — | — |
| Net earnings | −$23.0M | — | — |
| Operating cash flow | −$5.5M | — | — |
What changed
Revenue was $1.1M in Q4 2025, down 23% year over year and up 338% from the previous quarter.
Gross margin was 43.5%, up 3.5 points from Q4 2024. Operating costs exceeded revenue by $23.4M, an operating margin of -2057.5%. Operating expenses fell 30% while revenue fell 23%. The fastest-growing cost line was Research & development (+158%). The quarter ended with a net loss of $23.0M, wider than the previous quarter's $10.9M loss.
Operating cash flow was −$5.5M. Non-cash charges added back $563K of depreciation and amortization and $721K of share-based compensation. Working capital and other items added $16.1M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$7.0M.
Questions
What was Insight Molecular Diagnostics' revenue in the fourth quarter 2025?
Insight Molecular Diagnostics (IMDX) reported revenue of $1.1M for the fourth quarter 2025 (Q4 2025), -23% from a year earlier and +338% from the quarter before.